Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01127633
Registration number
NCT01127633
Ethics application status
Date submitted
19/05/2010
Date registered
21/05/2010
Titles & IDs
Public title
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Query!
Scientific title
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid ß Antibody in Patients With Alzheimer's Disease
Query!
Secondary ID [1]
0
0
H8A-MC-LZAO
Query!
Secondary ID [2]
0
0
11935
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
EXPEDITION EXT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Alzheimer's Disease
0
0
Query!
Condition category
Condition code
Neurological
0
0
0
0
Query!
Alzheimer's disease
Query!
Neurological
0
0
0
0
Query!
Dementias
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Solanezumab
Treatment: Drugs - Placebo
Experimental: Solanezumab -
Placebo comparator: Placebo -
Treatment: Drugs: Solanezumab
400 mg of solanezumab administered once every 4 weeks by intravenous infusion (IV) for up to 8 years.
Treatment: Drugs: Placebo
Participants were from feeder studies (LZAM or LZAN). Placebo administered intravenously every 4 weeks through Week 80.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Assess the Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs)
Query!
Assessment method [1]
0
0
The number of participants with 1 or more AEs assessed as related to the study drug and is summarized cumulatively. In addition, the number of participants with 1 or more serious AEs is summarized cumulatively. A serious AE is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Query!
Timepoint [1]
0
0
Baseline through Week 104
Query!
Secondary outcome [1]
0
0
Change From Baseline to 104-week Endpoint in Alzheimer's Disease Assessment Scale - Cognitive 14-Item Scale (ADAS-Cog14)
Query!
Assessment method [1]
0
0
ADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean was determined by mixed model repeated measures (MMRM) methodology with baseline, pooled investigator, treatment, visit, feeder visit 1 Mini-Mental State Examination (MMSE) status (mild/moderate), concomitant acetylcholinesterase inhibitors (AChEI)/Memantine use at baseline (yes/no), baseline age and treatment\*visit.
Query!
Timepoint [1]
0
0
Baseline, Week 104
Query!
Secondary outcome [2]
0
0
Change From Baseline to 104-week Endpoint in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL)
Query!
Assessment method [2]
0
0
ADCS-ADL is a 23-item inventory developed as a Rater-administered questionnaire answered by the participant's caregiver. It measures performance of basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. LS Mean was determined by MMRM methodology with baseline, pooled investigator, treatment, visit, feeder visit 1 MMSE status (mild/moderate), concomitant AChEI/Memantine use at baseline (yes/no), baseline age and treatment\*visit.
Query!
Timepoint [2]
0
0
Baseline, Week 104
Query!
Secondary outcome [3]
0
0
Change From Baseline to 104-week Endpoint in Clinical Dementia Rating - Sum of Boxes (CDR-SB)
Query!
Assessment method [3]
0
0
CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. LS Mean was determined by MMRM methodology with baseline, pooled investigator, treatment, visit, feeder visit 1 MMSE status (mild/moderate), concomitant AChEI/Memantine use at baseline (yes/no), baseline age and treatment\*visit.
Query!
Timepoint [3]
0
0
Baseline, Week 104
Query!
Secondary outcome [4]
0
0
Change From Baseline to 104-week Endpoint in Neuropsychiatric Inventory (NPI)
Query!
Assessment method [4]
0
0
The NPI is a questionnaire administered to caregivers that quantifies behavioral changes in dementia. Each of the 12 behavioral domains the caregiver reports as present are scored for Frequency, scale: 1 (Occasionally) to 4 (Very Frequently), and Severity, scale: 1 (Mild) to 3 (Severe). If the domain is reported by the caregiver as 'Not Affected,' that domain is scored as 0. The individual domain scores are calculated by multiplying the frequency times the severity for each domain. NPI Total Score is calculated by adding the individual domain scores together for all 12 domains, with a scores range from 0 to 144. Lower scores indicated less severity and higher scores indicated a greater severity of neuropsychiatric disturbance. LS Mean was determined by MMRM methodology with baseline, pooled investigator, treatment, visit, concomitant AChEI/Memantine use at baseline (yes/no), baseline age and treatment\*visit.
Query!
Timepoint [4]
0
0
Baseline, Week 104
Query!
Secondary outcome [5]
0
0
Change From Baseline to 104-week Endpoint in Resource Utilization in Dementia - Lite (RUD-Lite) Caregiver Hours
Query!
Assessment method [5]
0
0
The RUD-Lite is a caregiver-completed assessment designed to assess the amount of formal and informal resources used by participants and the primary caregiver. It is completed by the caregiver and compiles data on the following resources: length of time the caregiver spends giving care, assisting participants with basic activities of daily living (BADL: eating dressing, grooming, bathing); assisting participants with instrumental activities of daily living (IADLs: shopping, cooking, housekeeping, laundry, transportation, taking medication, managing finances), and providing supervision. Scores range from 0 to 24 hours. Higher values indicate greater resource use. LS Mean was determined by MMRM methodology with baseline, pooled investigator, treatment, visit, concomitant AChEI/Memantine use at baseline (yes/no), baseline age and treatment\*visit.
Query!
Timepoint [5]
0
0
Baseline, Week 104
Query!
Secondary outcome [6]
0
0
Change From Baseline to 104-week Endpoint in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy)
Query!
Assessment method [6]
0
0
EQ-5D (proxy version) is a generic, multidimensional, health-related, quality-of-life instrument assessing caregiver's impression of participants overall health state. Profile allows caregivers to rate participant's health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a 3-level scale: 1 (no problem), 2 (some problems), and 3 (major problems). These attribute combinations are converted into a weighted Health-State Index Score according to the United States (US) population-based algorithm. EQ-5D US Population-Based Index Scores range from -0.11 to 1.0. A score of 1.0 indicated perfect health. The Overall Health State Index Score is caregiver-reported using a visual analogue scale marked 0 (worst imaginable health) to 100 (best imaginable health state). LS Mean was determined by MMRM methodology with baseline, pooled investigator, treatment, visit, concomitant AChEI/Memantine use at baseline (yes/no), baseline age and treatment\*visit.
Query!
Timepoint [6]
0
0
Baseline, Week 104
Query!
Secondary outcome [7]
0
0
Change From Baseline to 104-week Endpoint in Quality of Life in Alzheimer's Disease (QoL-AD)
Query!
Assessment method [7]
0
0
The QoL-AD (Caregiver Total Score) is a disease-specific measure of quality of life for an Alzheimer's Disease (AD) population administered to the participant's primary caregiver, who answers on behalf of the participant. The assessment consists of 13 items covering physical health, energy, mood, living situations, memory, family, marriage, friends, chores, fun, money, self and life as a whole. The assessment is scored on a 4-point Likert scale with scores ranging from 1 (poor) to 4 (excellent). QoL-AD Total Score is defined as the sum of the 13 items with a scores range from 13 to 52. Higher scores denote a better quality of life. LS Mean was determined by MMRM methodology with baseline, pooled investigator, treatment, visit, concomitant AChEI/Memantine use at baseline (yes/no), baseline age and treatment\*visit.
Query!
Timepoint [7]
0
0
Baseline, Week 104
Query!
Secondary outcome [8]
0
0
Change From Baseline to 104-week Endpoint in Mini-Mental State Examination (MMSE)
Query!
Assessment method [8]
0
0
The MMSE is an instrument used to assess a participant's cognitive function. The instrument is divided into 2 sections. The first section measures orientation, memory, and attention with scores ranging from 0 to 21 (lower scores indicate greater impairment). The second section tests the ability of the participant to name objects, follow verbal and written commands, write a sentence, and copy figures with scores ranging from 0 to 9 (lower scores indicate greater impairment). The range for MMSE Total Score is 0 to 30. Lower scores indicate more impairment. LS Mean was determined by MMRM methodology with baseline, pooled investigator, treatment, visit, concomitant AChEI/Memantine use at baseline (yes/no), baseline age and treatment\*visit.
Query!
Timepoint [8]
0
0
Baseline, Week 104
Query!
Secondary outcome [9]
0
0
Change From Baseline to 52-week Endpoint in Plasma Amyloid Beta (Aß) Levels
Query!
Assessment method [9]
0
0
Concentration of the peptide Aß 1-40 and Aß 1-42 in plasma measured by immunoassay. The immunoassays for plasma Aß 1-40 and Aß 1-42 peptides were modified to render them tolerant to the presence of Solanezumab which would otherwise interfere with non-modified assays. LS Mean was determined by MMRM methodology with baseline, pooled investigator, treatment, visit, feeder visit 1 MMSE status (mild/moderate), concomitant AChEI/Memantine use at baseline (yes/no), baseline age and treatment\*visit.
Query!
Timepoint [9]
0
0
Baseline, Week 52
Query!
Secondary outcome [10]
0
0
Change From Baseline to 104-week Endpoint in Volumetric Magnetic Resonance Imaging (vMRI)
Query!
Assessment method [10]
0
0
The vMRI assessment of right and left hippocampal volume is reported. LS Mean was determined by MMRM methodology with baseline, pooled investigator, treatment, visit, feeder visit 1 MMSE status (mild/moderate), concomitant AChEI/Memantine use at baseline (yes/no), baseline age and treatment\*visit.
Query!
Timepoint [10]
0
0
Baseline, Week 104
Query!
Secondary outcome [11]
0
0
Change From Baseline to 104-week Endpoint in Alzheimer's Disease Assessment Scale - Cognitive Subscore 11-Item Scale (ADAS-Cog11)
Query!
Assessment method [11]
0
0
The cognitive subscale of the ADAS (ADAS Cog11) was used as a primary efficacy measure and consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease: orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. LS Mean was determined by MMRM methodology with baseline, pooled investigator, treatment, visit, feeder visit 1 MMSE status (mild/moderate), concomitant AChEI/Memantine use at baseline (yes/no), baseline age and treatment\*visit.
Query!
Timepoint [11]
0
0
Baseline, Week 104
Query!
Secondary outcome [12]
0
0
Mean Change From Baseline to Endpoint in Amyloid Imaging Parameters in Subjects With Mild Alzheimer's Disease
Query!
Assessment method [12]
0
0
Florbetapir PET imaging was used to test for change from baseline. The hypothesis that amyloid burden was reduced in participants between the treatment groups from the feeder studies was tested. The change from baseline to the postbaseline visit of the composite summary standard uptake value ratio of florbetapir F18 was calculated. The composite summary measure is an unweighted average of the 6 smaller regions (anterior cingulate, frontal medial orbital, parietal, posterior cingulate, precuneus, and temporal) normalized to whole cerebellum and to subject-specific white matter.
Query!
Timepoint [12]
0
0
Baseline, Week 104
Query!
Eligibility
Key inclusion criteria
* Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable Alzheimer's Disease
* Has completed participation in solanezumab Study LZAM or Study LZAN through 80 weeks
* Must continue to have a reliable caregiver who is in frequent contact with the patient for the entire study
* Must have good vein access to administer infusions
* Agrees not to participate in studies of any other investigational compounds for the duration of their participation in Study LZAO
Query!
Minimum age
55
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device (other than the study drug/device used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
* Meets LZAM or LZAN discontinuation criteria at the end of treatment in LZAM or LZAN study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/02/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1457
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Gosford
Query!
Recruitment hospital [2]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Kogarah
Query!
Recruitment hospital [3]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Chermside
Query!
Recruitment hospital [4]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Toowoomba
Query!
Recruitment hospital [5]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Box Hill
Query!
Recruitment hospital [6]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Glen Iris
Query!
Recruitment hospital [7]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Heidelberg Heights
Query!
Recruitment hospital [8]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Melbourne
Query!
Recruitment hospital [9]
0
0
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Subiaco
Query!
Recruitment postcode(s) [1]
0
0
2250 - Gosford
Query!
Recruitment postcode(s) [2]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [3]
0
0
4032 - Chermside
Query!
Recruitment postcode(s) [4]
0
0
4650 - Toowoomba
Query!
Recruitment postcode(s) [5]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [6]
0
0
3146 - Glen Iris
Query!
Recruitment postcode(s) [7]
0
0
3081 - Heidelberg Heights
Query!
Recruitment postcode(s) [8]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [9]
0
0
6008 - Subiaco
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Delaware
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
District of Columbia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Florida
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Georgia
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Indiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maryland
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Massachusetts
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Michigan
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Missouri
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Mexico
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New York
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
North Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Ohio
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Oklahoma
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oregon
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Pennsylvania
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Rhode Island
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
South Carolina
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
South Dakota
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Utah
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Vermont
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Virginia
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Washington
Query!
Country [30]
0
0
Argentina
Query!
State/province [30]
0
0
Buenos Aires
Query!
Country [31]
0
0
Argentina
Query!
State/province [31]
0
0
Ciudad Automona De Buenos Aire
Query!
Country [32]
0
0
Argentina
Query!
State/province [32]
0
0
Cordoba
Query!
Country [33]
0
0
Argentina
Query!
State/province [33]
0
0
Mendoza
Query!
Country [34]
0
0
Argentina
Query!
State/province [34]
0
0
Rosario
Query!
Country [35]
0
0
Argentina
Query!
State/province [35]
0
0
Santa Fe
Query!
Country [36]
0
0
Brazil
Query!
State/province [36]
0
0
Curitiba
Query!
Country [37]
0
0
Brazil
Query!
State/province [37]
0
0
Itapira
Query!
Country [38]
0
0
Brazil
Query!
State/province [38]
0
0
Porto Alegre
Query!
Country [39]
0
0
Brazil
Query!
State/province [39]
0
0
Rio De Janeiro
Query!
Country [40]
0
0
Brazil
Query!
State/province [40]
0
0
São Paulo
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Alberta
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
British Columbia
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
Ontario
Query!
Country [44]
0
0
Canada
Query!
State/province [44]
0
0
Quebec
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Paris
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Rennes
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Strasbourg
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Toulouse
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Berlin
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Hamburg
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Hannover
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Mannheim
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Munich
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Regensburg
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Baggiovara
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Biella
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Chieti
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Genova
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Lido Di Camaiore
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Milano
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Rome
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Aichi
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Ehime
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Fukuoka
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Hiroshima
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Hyogo
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Kanagawa
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Kyoto
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Osaka
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Shizuoka
Query!
Country [71]
0
0
Japan
Query!
State/province [71]
0
0
Tokyo
Query!
Country [72]
0
0
Korea, Republic of
Query!
State/province [72]
0
0
Incheon
Query!
Country [73]
0
0
Korea, Republic of
Query!
State/province [73]
0
0
Seongnam-Si
Query!
Country [74]
0
0
Korea, Republic of
Query!
State/province [74]
0
0
Seoul
Query!
Country [75]
0
0
Korea, Republic of
Query!
State/province [75]
0
0
Suwon-Si
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Bydgoszcz
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Gliwice
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Katowice
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Krakow
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Lublin
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Warsaw
Query!
Country [82]
0
0
Russian Federation
Query!
State/province [82]
0
0
Chelyabinsk
Query!
Country [83]
0
0
Russian Federation
Query!
State/province [83]
0
0
Saint Petersburg
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Barcelona
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Getafe
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Madrid
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Plasencia
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Terrassa
Query!
Country [89]
0
0
Sweden
Query!
State/province [89]
0
0
Jönköping
Query!
Country [90]
0
0
Sweden
Query!
State/province [90]
0
0
Kalmar
Query!
Country [91]
0
0
Sweden
Query!
State/province [91]
0
0
Lund
Query!
Country [92]
0
0
Sweden
Query!
State/province [92]
0
0
Molndal
Query!
Country [93]
0
0
Sweden
Query!
State/province [93]
0
0
Umea
Query!
Country [94]
0
0
Taiwan
Query!
State/province [94]
0
0
Guishan
Query!
Country [95]
0
0
Taiwan
Query!
State/province [95]
0
0
Niaosong
Query!
Country [96]
0
0
Taiwan
Query!
State/province [96]
0
0
Taipei
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
E Susx
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Glasgow
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Greater London
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Eli Lilly and Company
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is an open-label extension study in Alzheimer's patients who have completed participation in either solanezumab Clinical Trial H8A-MC-LZAM (NCT00905372) or H8A-MC-LZAN (NCT00904683).
Query!
Trial website
https://clinicaltrials.gov/study/NCT01127633
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Query!
Address
0
0
Eli Lilly and Company
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Query!
Available to whom?
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://vivli.org/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01127633